Antibody therapy for hypertrophic adipocytes

About Alytas Therapeutics

Alytas Therapeutics is a preclinical-stage biotech developing a first-in-class antibody therapy designed to selectively eliminate hypertrophic adipocytes, aiming to treat the root cause of obesity and its metabolic complications. Founded as a spin-off from the University Hospital Jena, the company is advancing a unique immunological concept identified in patient samples and verified in vitro. It operates through strategic collaborations with partners like VERAXA GmbH for antibody development and CureDiab for in vitro characterization, targeting a massive and growing global market burdened by high healthcare costs.

Therapeutic Areas